# Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

Source: https://onco.cc/trials/nct07101432/  
OnCo record `nct07101432` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is recruiting.

## Summary

The registry lists NCT07101432 as recruiting, last updated 2026-10-05. Enrolment is 33 planned participants, an estimate. Interventions: Fludarabine, Cyclophosphamide. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications. The brief summary specifies TROP2 CAR/IL-15 TGFBR2-knockout cord-blood NK cells with radiation; the intervention list names only the lymphodepleting drugs.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT07101432
- Phase: 1
- Setting: Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)
- Sponsor: M.D. Anderson Cancer Center

## Sources

- ClinicalTrials.gov NCT07101432: https://clinicaltrials.gov/study/NCT07101432

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/nct07101432.json